Through agreements with qualified institutions, the Foundation has launched three support services for its research network:
CFaCORE: a centralized facility for the use of animal models, transferring basic knowledge to preclinical applications and promoting the development of new therapeutic strategies
Primary Cell Cultures Service: dedicated to the preparation and distribution of primary respiratory epithelial cultures, providing researchers with cellular models closely resembling the bronchial epithelium in vivo
CFDB: an online consultation tool enabling quick and detailed searches of all cystic fibrosis clinical trials
NEXT-CF: a service for clinicians offering ex vivo theratyping to support personalized treatment for people with cystic fibrosis carrying rare CFTR variants
The Facility offers researchers studying cystic fibrosis a collection of primary cell cultures derived from bronchial epithelium, both from individuals with CF and from control subjects who have undergone lung transplantation.
NEXT-CF. NASAL EPITHELIUM EX VIVO THERATYPING FOR CYSTIC FIBROSIS
Next-CF provides clinicians with an ex vivo theratyping service that helps identify the most suitable treatment for people with CF who carry rare CFTR variants, anticipate which individuals are unlikely to respond to available modulators, and build a valuable biobank of cellular models for testing future therapies.
The CFaCore (Cystic Fibrosis animal Core Facility) service provides a range of expertise, services and infrastructure to enable researchers working on cystic fibrosis studies to use preclinical animal (murine) models of the disease for pathogenetic and therapeutic research.
The Cystic Fibrosis DataBase (CFDB) service has the purpose to describe the state of the art of clinical research in cystic fibrosis (CF) and to provide a general summary of the current findings and of areas that require further studies.
The Service provides the FFC Ricerca network researchers with a collection of primary cell cultures obtained from the CF and non-CF human bronchial epithelial cells, using explanted lungs from patients who have undergone lung transplantation.
